MetaVia (MTVA) Notes Payables (2015 - 2016)

MetaVia's (MTVA) quarterly Notes Payables came in at $6.8 million in Q2 2016, up 280.67% on a QoQ basis from $1.8 million in Q4 2015.

MetaVia (MTVA) Notes Payables (2015 - 2016) Analysis & Trends

MetaVia (MTVA) has 2 years of Notes Payables data on file, last reported at $6.8 million in Q2 2016.

Quarterly Notes Payables changed N/A year-over-year to $6.8 million in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $6.8 million (changed N/A YoY) and the FY2015 annual result came in at $1.8 million, changed N/A from the prior year.
Notes Payables grew to $6.8 million in Q2 2016, from $1.8 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $6.8 million in Q2 2016 to a low of $1.8 million in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	MetaVia	8.72 Mn	-3.92 Mn	-

Download Data

Date	Value
Jun 30, 2016	6.83 Mn
Dec 31, 2015	1.80 Mn